Okusanya Babasola O, Lott Breanne E, Ehiri John, McClelland Jean, Rosales Cecilia
Department of Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, United States.
Health Sciences Library, University of Arizona, Tucson, AZ, United States.
Front Neurol. 2022 May 30;13:871187. doi: 10.3389/fneur.2022.871187. eCollection 2022.
Medical cannabis (MC) has been hypothesized as an alternative therapy for migraines, given the undesirable side effects of current migraine medications. The objective of this review was to assess the effectiveness and safety of MC in the treatment of migraine in adults.
We searched PubMed, EMBASE, PsycINFO, CINAHL, and Web of Science for eligible studies in adults aged 18 years and older. Two reviewers independently screened studies for eligibility. A narrative synthesis of the included studies was conducted.
A total of 12 publications involving 1,980 participants in Italy and the United States of America were included.Medical cannabis significantly reduced nausea and vomiting associated with migraine attacks after 6 months of use. Also, MC reduced the number of days of migraine after 30 days, and the frequency of migraine headaches per month. MC was 51% more effective in reducing migraines than non-cannabis products. Compared to amitriptyline, MC aborted migraine headaches in some (11.6%) users and reduced migraine frequency. While the use of MC for migraines was associated with the occurrence of medication overuse headaches (MOH), and the adverse events were mostly mild and occurred in 43.75% of patients who used oral cannabinoid preparations.
There is promising evidence that MC may have a beneficial effect on the onset and duration of migraine headaches in adults. However, well-designed experimental studies that assess MC's effectiveness and safety for treating migraine in adults are needed to support this hypothesis.
鉴于目前偏头痛药物存在不良副作用，医用大麻被认为是偏头痛的一种替代疗法。本综述的目的是评估医用大麻在治疗成人偏头痛方面的有效性和安全性。
我们在PubMed、EMBASE、PsycINFO、CINAHL和Web of Science中检索了18岁及以上成年人的合格研究。两名评审员独立筛选研究的合格性。对纳入的研究进行了叙述性综合分析。
共纳入了12篇涉及意大利和美国1980名参与者的出版物。使用6个月后，医用大麻显著减轻了与偏头痛发作相关的恶心和呕吐。此外，医用大麻在30天后减少了偏头痛天数以及每月偏头痛发作的频率。与非大麻产品相比，医用大麻在减轻偏头痛方面的效果要高出51%。与阿米替林相比，医用大麻使部分（11.6%）使用者的偏头痛发作中止，并降低了偏头痛发作频率。虽然使用医用大麻治疗偏头痛与药物过量使用性头痛（MOH）的发生有关，且不良事件大多较轻，发生在43.75%使用口服大麻素制剂的患者中。
有证据表明医用大麻可能对成人偏头痛的发作和持续时间有有益影响。然而，需要设计良好的实验研究来评估医用大麻治疗成人偏头痛的有效性和安全性，以支持这一假设。
